Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1 Dermatologic 1

Conditions

Interventions

aldesleukin 69 Cyclophosphamide 50 fludarabine phosphate 36 fludarabine 30 Interleukin-2 27 incomplete Freund's adjuvant 22 Ipilimumab 20 Biopsy 20 Specimen Handling 19 Magnetic Resonance Spectroscopy 19 MART-1 Antigen 15 CTLA-4 Antigen 15 sargramostim 14 Nivolumab 13 Filgrastim 13 montanide ISA 51 12 Sorafenib 12 Interferon-alpha 11 pembrolizumab 10 trametinib 9 Temozolomide 9 Bevacizumab 9 dabrafenib 8 temsirolimus 7 Sirolimus 7 Gene Expression Profiling 7 tanespimycin 6 Paclitaxel 6 Dacarbazine 6 Cisplatin 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

NIH × saponin QA-21V1 × Dermatologic × Clear all

NCT00005052 2009-02-09

Vaccine Therapy in Treating Patients With Primary Stage II Melanoma

National Cancer Institute (NCI)

Phase 3 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡